Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3618-3625

  Malkevich, Nina V ^a   Hopkins, Robert J ^a   Bernton, Edward ^a   Meister, Gabriel T ^b   Vela, Eric M ^b   Atiee, George ^c   Johnson, Virginia ^a   Nabors, Gary S ^a   Aimes, Ronald T ^a   Ionin, Boris ^a   Skiadopoulos, Mario H ^a  

^a Emergent Biosolutions   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c Worldwide Clinical Trials Drug Development Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; AVP 21D9; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVP-21D9; BACTERIAL ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; CONTACT DERMATITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERECTILE DYSFUNCTION; FEMALE; FOLLICULITIS; GASTROENTERITIS; HEADACHE; HEAT EXHAUSTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMB INJURY; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; NOSE OBSTRUCTION; OROPHARYNX PAIN; PAIN; PELVIC PAIN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; UTERUS BLEEDING; VERTIGO; VIRAL UPPER RESPIRATORY TRACT INFECTION; VULVOVAGINITIS; ADOLESCENT; ADULT; ANIMAL; BACTEREMIA; BLOOD; CHO CELL LINE; CLINICAL TRIAL; CRICETULUS; DOSE RESPONSE; HAMSTER; IMMUNOLOGY; MIDDLE AGED; RABBIT; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACTEREMIA; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MIDDLE AGED; RABBITS; YOUNG ADULT;

EID: 84903151820     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02295-13     Document Type: Article

References (28)

1. Grabenstein JD. 2008. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 46:129-136. http://dx.doi.org/10.1086/ 523578.
2. Dixon TC, Meselson M, Guillemin J, Hanna PC. 1999. Anthrax. N. Engl. J. Med. 341:815-826. http://dx.doi.org/10.1056/NEJM199909093411107. (Pubitemid 29420478)
3. Bann JG, Hultgren SJ. 2004. Structural biology: anthrax hijacks host receptor. Nature 430:843-844. http://dx.doi.org/10.1038/430843a. (Pubitemid 39119203)
4. Brossier F, Mock M. 2001. Toxins of Bacillus anthracis. Toxicon 39:1747-1755. http://dx.doi.org/10.1016/S0041-0101(01)00161-1. (Pubitemid 32787006)
5. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C, Griffith KS, Guarner J, Hadler JL, Hayslett JA, Meyer R, Petersen LR, Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh WJ, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K, Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes J, Fleming D, Koplan JP, Gerberding JL, National Anthrax Epidemiologic Investigation Team. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028. http://dx.doi.org/10. 3201/eid0810.020353. (Pubitemid 35256987)
6. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin SK, Sejvar JJ, Shepard CW, McConnell M, Guarner J, Shieh WJ, Malecki JM, Gerberding JL, Hughes JM, Perkins BA, Anthrax Bioterrorism Investigation Team. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944. http://dx.doi.org/10.3201/eid0706. 010604. (Pubitemid 33115771)
7. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc. Natl. Acad. Sci. U. S. A. 90:2291-2294. http://dx.doi.org/10.1073/pnas.90.6. 2291. (Pubitemid 23078612)
8. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K, Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252. http://dx.doi.org/10.1001/jama.287.17.2236. (Pubitemid 34441940)
9. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 361:135-144. http://dx.doi.org/10.1056/NEJMoa0810603.
10. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73: 795-802. http://dx.doi.org/10.1128/IAI.73.2.795-802.2005. (Pubitemid 40165735)
11. Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, Guarner J, Wilkins P, Norville KJ, Barr JR, Zaki SR, Patel JB, Reagan SP, Pirkle JL, Treadwell TA, Messonnier NR, Rotz LD, Meyer RF, Stephens DS. 2007. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin. Infect. Dis. 44:968-971. http://dx.doi.org/10.1086/512372. (Pubitemid 46452063)
12. Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH. 2013. Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob. Agents Chemother. 57:5684-5692. http://dx.doi.org/10.1128/AAC.00458-13.
13. Corey A, Migone TS, Bolmer S, Fiscella M, Ward C, Chen C, Meister G. 2013. Bacillus anthracis protective antigen kinetics in inhalation sporechallenged untreated or levofloxacin/raxibacumab-treated New Zealand white rabbits. Toxins (Basel) 5:120-138. http://dx.doi.org/10.3390/toxins5010120.
14. Sawada-Hirai R, Jiang I, Wang F, Sun SM, Nedellec R, Ruther P, Alvarez A, Millis D, Morrow PR, Kang AS. 2004. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines 2:1-15.
15. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J. 2006. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. 74:1016-1024. http://dx.doi.org/10.1128/IAI. 74.2.1016-1024.2006. (Pubitemid 43185538)
16. Goossens PL. 2009. Animal models of human anthrax: the Quest for the Holy Grail. Mol. Aspects Med. 30:467-480. http://dx.doi.org/10.1016/j.mam.2009.07. 005.
17. Bergman KL. 2009. The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose. Clin. Pharmacol. Ther. 86:328-331. http://dx.doi.org/10.1038/clpt.2009.106.
18. FDA. 2009. Guidance for industry: animal models-essential elements to address efficacy under the animal rule. Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078923.pdf.
19. Twenhafel NA. 2010. Pathology of inhalation anthrax in animal models. Vet. Pathol. 47:819-830. http://dx.doi.org/10.1177/0300985810378112.
20. Comer JE, Ray BD, Henning LN, Stark GV, Barnewall RE, Mott JM, Meister GT. 2012. Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand White rabbits as a trigger for treatment. Clin. Vaccine Immunol. 19:1517-1525. http://dx.doi.org/10.1128/CVI. 00292-12.
21. Henning LN, Comer JE, Stark GV, Ray BD, Tordoff KP, Knostman KA, Meister GT. 2012. Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaques. Clin. Vaccine Immunol. 19:1765-1775. http://dx.doi.org/10.1128/CVI.00288-12.
22. Peterson JW, Comer JE, Baze WB, Noffsinger DM, Wenglikowski A, Walberg KG, Hardcastle J, Pawlik J, Bush K, Taormina J, Moen S, Thomas J, Chatuev BM, Sower L, Chopra AK, Stanberry LR, Sawada R, Scholz WW, Sircar J. 2007. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect. Immun. 75:3414-3424. http://dx.doi.org/10.1128/IAI.00352-07. (Pubitemid 47040942)
23. Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, Green T, Rubinstein LJ, Caulfield MJ, Sikkema D. 2009. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulinGserotype-specific antipneumococcal antibodies in human serum. Clin. Vaccine Immunol. 16:387-396. http://dx.doi.org/10.1128/CVI.00415-08.
24. Li H, Soroka SD, Taylor TH, Jr, Stamey KL, Stinson KW, Freeman AE, Abramson DR, Desai R, Cronin LX, Oxford JW, Caba J, Pleatman C, Pathak S, Schmidt DS, Semenova VA, Martin SK, Wilkins PP, Quinn CP. 2008. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J. Immunol. Methods 333: 89-106. http://dx.doi.org/10.1016/j. jim.2008.01.007.
25. Omland KS, Brys A, Lansky D, Clement K, Lynn F, Participating Laboratories. 2008. Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species. Clin. Vaccine Immunol. 15:946-953. http://dx.doi.org/10.1128/CVI.00003- 08.
26. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, Nielsen C, Carnes R, Carney J. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 83:1201-1209. http://dx.doi.org/10.1097/01.LAB. 0000080599.43791.01. (Pubitemid 37013055)
27. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992. (Pubitemid 28521045)
28. Yee SB, Hatkin JM, Dyer DN, Orr SA, Pitt ML. 2010. Aerosolized Bacillus anthracis infection in New Zealand White rabbits: natural history and intravenous levofloxacin treatment. Comp. Med. 60:461-468.